Last $23.47 USD
Change Today -0.03 / -0.13%
Volume 2.6K
GLAXF On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GLAXF) Snapshot

Open
$23.20
Previous Close
$23.50
Day High
$23.57
Day Low
$22.95
52 Week High
03/5/14 - $28.56
52 Week Low
10/15/14 - $21.22
Market Cap
114.1B
Average Volume 10 Days
6.9K
EPS TTM
--
Shares Outstanding
4.9B
EX-Date
02/19/15
P/E TM
--
Dividend
$94.03
Dividend Yield
6.27%
Current Stock Chart for GLAXOSMITHKLINE PLC (GLAXF)

glaxosmithkline plc (GLAXF) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc (GLAXF) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc (GLAXF) Key Developments

Clovis Oncology and GlaxoSmithKline Enter into Clinical Trial Collaboration

Clovis Oncology (CLVS) and GlaxoSmithKline (GSK) announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in the first half of 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI). This clinical trial is designed to test the hypothesis that the combination of two oral drugs targeting different cellular growth pathways, both often active in EGFR mutant NSCLC, will lead to augmented clinical benefit.

Several Companies Reportedly Eyes Mature Drugs of GlaxoSmithKline

Apollo Global Management, LLC (NYSE:APO) and other bidders intend to make an offer for all of the mature drugs of GlaxoSmithKline plc (LSE:GSK). The deal could be values at more than $3 billion, according to sources with direct knowledge of the situation. Apollo plans to acquire all of the products for sale while other suitors are only interested in purchasing regional businesses. The final offers will be accepted by GSK by early next week, the sources told Reuters. Other bidders include H. Lundbeck A/S (CPSE:LUN) and Kohlberg Kravis Roberts & Co. L.P. (NYSE:KKR) which has teamed up with manufacturer Norgine Pharmaceuticals Limited. Lupin Limited (NSE:LUPIN) was also interested in the auction, but at this point it is unclear if it is still taking part. GSK has appointed with Lazard Ltd to handle the auction and is hoping to find a buyer before the end of 2014. M&A Navigator added that spokesperson for GSK declined to comment. Representatives for Apollo, Norgine and Lundbeck did not comment when reached by Reuters, while KKR was unavailable for comment.

Apollo Global Reportedly Seeks To Acquire GSK's Mature Drugs

Apollo Global Management, LLC (NYSE:APO) is planning to bid for allGlaxoSmithKline plc (LSE:GSK) mature drugs, joining an auction expected to value the business at more than $3 billion, Reuters reproted citing four people familiar with the process. The private equity firm, run by Leon Black, could change the dynamic of the auction because it is ready to buy all the products on offer, while other potential buyers are looking to acquire only certain regional businesses. Apollo, GSK declined to comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLAXF:US $23.47 USD -0.03

GLAXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $160.16 USD +0.80
AbbVie Inc $67.36 USD +2.17
Bayer AG €117.17 EUR +3.34
Celgene Corp $108.20 USD +0.85
Novo Nordisk A/S kr265.80 DKK +2.00
View Industry Companies
 

Industry Analysis

GLAXF

Industry Average

Valuation GLAXF Industry Range
Price/Earnings 16.7x
Price/Sales 2.9x
Price/Book 13.6x
Price/Cash Flow 16.6x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.